Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Serum beta-2-microglobulin in multiple myeloma. Practical value].

R Bataille, M Magub, J Sany

    Revue Du Rhumatisme Et Des Maladies Osteo-Articulaires
    |March 1, 1981
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Differential benefit of adjuvant everolimus according to endocrine therapy backbone in the randomized UNIRAD trial.

    ESMO open·2025
    Same author

    Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial.

    Annals of oncology : official journal of the European Society for Medical Oncology·2024
    Same author

    Prognostic value of EndoPredict test in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer screened for the randomized, double-blind, phase III UNIRAD trial.

    ESMO open·2024
    Same author

    Correction: Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program.

    Oncogene·2023
    Same author

    Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program.

    Oncogene·2023
    Same author

    Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer.

    Annals of oncology : official journal of the European Society for Medical Oncology·2018
    Same journal

    Joint manifestations of bacillus funduliformis.

    Revue du rhumatisme et des maladies osteo-articulaires·2010
    Same journal

    Rheumatism of focal prostatic origin.

    Revue du rhumatisme et des maladies osteo-articulaires·2010
    Same journal

    Micromic dwarfism of exostosic origin.

    Revue du rhumatisme et des maladies osteo-articulaires·2010
    Same journal

    Of the choice of surgical intervention with regard to rebellious rheumatic sciatica.

    Revue du rhumatisme et des maladies osteo-articulaires·2010
    Same journal

    A newcomer to rheumatology; Hench and Rosenberg's palindromic rheumatism.

    Revue du rhumatisme et des maladies osteo-articulaires·2010
    Same journal

    Combined treatment of purulent arthritis by general sulfamidotherapy and intra-articular and shock treatment.

    Revue du rhumatisme et des maladies osteo-articulaires·2010
    See all related articles

    Serum beta-2-microglobulin (S beta 2m) levels are elevated in multiple myeloma (MM) and correlate with tumor mass. While not ideal for diagnosing benign monoclonal gammopathy versus MM, S beta 2m aids MM prognosis and treatment monitoring.

    Area of Science:

    • Hematology
    • Clinical Chemistry
    • Oncology

    Background:

    • Multiple myeloma (MM) is a hematologic malignancy characterized by uncontrolled plasma cell proliferation.
    • Accurate assessment of tumor burden and treatment response is crucial for managing MM.
    • Serum beta-2-microglobulin (S beta 2m) is a protein found on the surface of most nucleated cells, often elevated in conditions with high cell turnover.

    Purpose of the Study:

    • To evaluate the diagnostic and prognostic utility of serum beta-2-microglobulin (S beta 2m) and the S beta 2m/theoretical S beta 2m M/TH ratio in patients with multiple myeloma (MM).
    • To compare S beta 2m levels in MM patients with healthy controls and patients with benign monoclonal gammopathy.
    • To assess the correlation of S beta 2m with tumor mass and response to chemotherapy in MM.

    Main Methods:

    Related Experiment Videos

    • Serum beta-2-microglobulin (S beta 2m) concentrations and the S beta 2m/theoretical S beta 2m M/TH ratio were measured in 69 MM patients, healthy subjects, and patients with benign monoclonal gammopathy.
    • Statistical analysis was performed to compare groups and assess correlations with plasma cell mass and treatment response.

    Main Results:

    • S beta 2m concentration and the S beta 2m M/TH ratio were significantly higher in MM patients compared to controls.
    • No significant difference in S beta 2m or the ratio was observed between benign monoclonal gammopathy and early-stage MM (Stage I of Durie and Salmon criteria).
    • Changes in S beta 2m levels and the ratio during chemotherapy strongly correlated with changes in tumor mass.

    Conclusions:

    • Serum beta-2-microglobulin is not highly effective for differentiating benign monoclonal gammopathy from multiple myeloma.
    • S beta 2m is a valuable prognostic marker in MM, enabling accurate assessment of tumor burden and treatment efficacy, especially when conventional markers are deficient.